Editas Medicine Inc EDIT:NASDAQ

Last Price$24.99NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/20/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$23.30 (1)
Ask (Size)$26.08 (5)
Day Low / HighN/A - N/A
Volume1.9 M

View Biotechnology IndustryPeer Comparison as of 09/20/2019


Editas Medicine Inc ( NASDAQ )

Price: $24.99
Change: -0.19 (0.75%)
Volume: 1.9 M
4:00PM ET 9/20/2019

Sangamo Therapeutics Inc ( NASDAQ )

Price: $10.66
Change: +0.03 (0.28%)
Volume: 2.2 M
4:00PM ET 9/20/2019

OPKO Health Inc ( NASDAQ )

Price: $2.02
Change: -0.03 (1.46%)
Volume: 10.5 M
4:00PM ET 9/20/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Veracyte Inc ( NASDAQ )

Price: $26.50
Change: +0.45 (1.73%)
Volume: 1.1 M
4:00PM ET 9/20/2019

Read more news Recent News

Editas Medicine Starts Investigational New Drug Work for EDIT-301 to Treat Sickle Cell, Beta-Thalassemia
5:57AM ET 6/17/2019 MT Newswires

Editas Medicine (EDIT), a developer of therapies for genetically defined diseases, said Saturday it has started activities for its investigational new drug...

Analyst Actions: Evercore ISI Initiates Coverage on Editas Medicine With Outperform Rating
11:49AM ET 4/12/2019 MT Newswires

Editas Medicine's (EDIT) average rating among analysts is a buy, with an average price target of $40. Price: 26.19, Change: +0.70, Percent Change: +2.75...

Editas Medicine, BlueRock Therapeutics Ink Research, Cross-Licensing Deal To Combine Genome Editing And Cell Therapy Platforms
8:56AM ET 4/03/2019 MT Newswires

Editas Medicine (EDIT) and BlueRock Therapeutics, an engineered cell therapy company, said they have entered into a strategic research partnership and...

Insider Trends: Editas Medicine Sees Insider Acquisition Interrupting 90-Days of Sells
4:07PM ET 3/07/2019 MT Newswires

On Mar 05, 2019, Dr Jessica Hopfield, Director, bought 10,200 shares in Editas Medicine (EDIT) for $244,188. Dr Hopfield, subsequent to the transactions...

View all Commentary and Analysis

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2019 Update
4:40PM ET 9/09/2019 Seeking Alpha

Editas Medicine (EDIT) Investor Presentation - Slideshow
1:47PM ET 9/09/2019 Seeking Alpha

Genomic Medicine: Fall 2019 Tracking Update
11:04AM ET 9/04/2019 Seeking Alpha

Editas Medicine: A Good Proxy For The Gene Editing Space
8:04PM ET 9/03/2019 Seeking Alpha

Company Profile

Business DescriptionEditas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA. View company web site for more details
Address11 Hurley Street
Cambridge, Massachusetts 02142
Number of Employees133
Recent SEC Filing09/13/20194
President, Chief Executive Officer & DirectorCynthia L. Collins
Interim Chief Financial & Accounting OfficerEric Ek
Chief Technology OfficerVic Myer
Chief Scientific OfficerCharles Albright

Company Highlights

Price Open$25.16
Previous Close$25.18
52 Week Range$17.80 - 33.75
Market Capitalization$1.2 B
Shares Outstanding49.5 M
SectorHealth Technology
Next Earnings Announcement11/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.13
Beta vs. S&P 500N/A
Revenue$31.9 M
Net Profit Margin-412.70%
Return on Equity-47.46%

Analyst Ratings as of 09/05/2019

Consensus RecommendationConsensus Icon
Powered by Factset